Biopharma IPO activity slows, but 2025 returns are surging

Sep. 9, 2025

Although 2024 showed signs of recovery, 2025 is once again reflecting an IPO slowdown, with global biopharma IPO proceeds in the first seven months of the year falling to their lowest level since 2016.

BioWorld Analysis and data insight Financings IPO

Today's news in brief

BioWorld

BioWorld briefs for Nov. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 12, 2025.

‘Most complete’ map of oral microbiome enables links to systemic disease

BioWorld

South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes....

Antibody-drug conjugates floating on light purple background

Sutro Biopharma outlines ADC pipeline

BioWorld Science

Sutro Biopharma Inc. has outlined its next-generation antibody-drug conjugate (ADC) pipeline following recent IND clearance and initiation of phase I for its...

Gentibio’s GNTI-823 promotes renal repair in AKI models

BioWorld Science

Gentibio Inc. has developed and presented data for GNTI-823, an allogeneic tissue Treg engineered from peripheral blood CD4+ T cells with CRISPR-based editing to...